Created at	Source	Raw Value	Validated value
Oct. 26, 2020, 11:31 p.m.	usa	Safety: Proportion of participants with grade 3 or more adverse events;Efficacy: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2	Safety: Proportion of participants with grade 3 or more adverse events;Efficacy: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2